HDAC6 Modulation Therapy for Neurodegeneration

HDAC6 Modulation Therapy for Neurodegeneration

Overview

This therapeutic concept targets HDAC6 (Histone Deacetylase 6) to restore neuronal proteostasis, microtubule function, and stress resilience in Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. HDAC6 is uniquely located in the cytoplasm where it deacetylates key substrates including α-tubulin, [Hsp90](entities/hsp90-protein), and tau, making it a pivotal regulator of autophagy, protein clearance, and cellular stress responses[@simespires2013][@dydewalle2012].

Target

• Primary Target: HDAC6 enzymatic activity
• Modality: Selective HDAC6 inhibitors (small molecules)
• Indication: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, [Huntington's disease](diseases/huntingtons), aging-linked cognitive decline

Mechanistic Rationale

HDAC6's Unique Role in Neuronal Health

HDAC6 differs from other HDACs in several critical ways:

Primarily cytoplasmic location — not a nuclear histone deacetylase

Substrate diversity — deacetylates tubulin, Hsp90, tau, CFTR, and others

Regulates autophagy — controls autophagosome-lysosome fusion

Modulates Hsp90 — affects protein folding quality control

Key Mechanisms

1. Microtubule Function Restoration

HDAC6 deacetylates α-tubulin, and HDAC6 inhibition restores tubulin acetylation levels:

• Improves axonal transport of organelles, vesicles, and proteins
• Enhances mitochondrial distribution in neurons
• Restores synaptic vesicle trafficking

...

HDAC6 Modulation Therapy for Neurodegeneration

Overview

This therapeutic concept targets HDAC6 (Histone Deacetylase 6) to restore neuronal proteostasis, microtubule function, and stress resilience in Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. HDAC6 is uniquely located in the cytoplasm where it deacetylates key substrates including α-tubulin, [Hsp90](entities/hsp90-protein), and tau, making it a pivotal regulator of autophagy, protein clearance, and cellular stress responses[@simespires2013][@dydewalle2012].

Target

• Primary Target: HDAC6 enzymatic activity
• Modality: Selective HDAC6 inhibitors (small molecules)
• Indication: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, [Huntington's disease](diseases/huntingtons), aging-linked cognitive decline

Mechanistic Rationale

HDAC6's Unique Role in Neuronal Health

HDAC6 differs from other HDACs in several critical ways:

Primarily cytoplasmic location — not a nuclear histone deacetylase

Substrate diversity — deacetylates tubulin, Hsp90, tau, CFTR, and others

Regulates autophagy — controls autophagosome-lysosome fusion

Modulates Hsp90 — affects protein folding quality control

Key Mechanisms

1. Microtubule Function Restoration

HDAC6 deacetylates α-tubulin, and HDAC6 inhibition restores tubulin acetylation levels:

• Improves axonal transport of organelles, vesicles, and proteins
• Enhances mitochondrial distribution in neurons
• Restores synaptic vesicle trafficking

2. Hsp90 Function Normalization

Hsp90 hyperacetylation due to HDAC6 overactivity leads to:

• Degraded [Hsp90](entities/hsp90-protein) client protein quality control
• Accelerated accumulation of misfolded proteins
• HDAC6 inhibition normalizes Hsp90 acetylation and chaperone function

3. Autophagy Enhancement

HDAC6 regulates autophagosome-lysosome fusion through:

• Controlling the acetylation status of core autophagy proteins
• Facilitating cargo recruitment
• HDAC6 inhibition promotes clearance of protein aggregates

4. Tau Pathology Reduction

HDAC6 deacetylates tau at multiple sites:

• Hyperacetylated tau is more prone to aggregation
• HDAC6 inhibition reduces tau acetylation and aggregation
• Promotes tau clearance via enhanced autophagy

Disease Relevance

Alzheimer's Disease

HDAC6 is elevated in AD brains and contributes to multiple pathological processes[@govindarajan2013][@zhang2017]:

• Impaired axonal transport in neurons
• Reduced autophagic clearance of amyloid-beta and tau
• Mitochondrial dysfunction
• Synaptic plasticity deficits

HDAC6 inhibitors have shown efficacy in:

• APP/PS1 mice: Reduced amyloid plaques and improved cognition
• Tauopathy models: Decreased tau aggregation and phosphorylation
• Primary neurons: Restored axonal transport

Parkinson's Disease

In PD models, HDAC6 inhibition addresses[@chen2020][@du2020]:

• Alpha-synuclein aggregation
• Mitochondrial dysfunction in dopaminergic neurons
• Autophagy-lysosomal pathway impairment
• Axonal transport deficits

Studies show:

• Protection against MPTP toxicity
• Reduced alpha-synuclein inclusions
• Improved mitochondrial function

ALS

HDAC6 modulation shows promise in ALS through[@taes2013]:

• Restoring axonal transport of RNA granules
• Enhancing autophagy of misfolded SOD1
• Protecting motor neuron connectivity
• Modulating stress granule dynamics

Huntington's Disease

HDAC6 is a particularly strong target in HD[@dompierre2007]:

• Mutant huntingtin aggregates impair autophagy
• HDAC6 inhibition enhances clearance
• Improves motor function in models

Clinical Development Path

Preclinical Requirements

In vitro:

• HDAC6 activity assays in patient-derived neurons
• Alpha-synuclein and tau aggregation models
• Axonal transport assays (live cell imaging)
• Autophagy flux measurements

Animal models:

• APP/PS1 mice for AD
• MPTP/α-synuclein models for PD
• SOD1 G93A mice for ALS
• R6/2 mice for HD
• Measures: cognitive testing, motor function, pathology, acetylation status

Clinical Phases

| Phase | Design | Participants | Endpoints |
|-------|--------|--------------|------------|
| Phase 1 | Single ascending dose | Healthy volunteers | Safety, PK, target engagement (platelet HDAC6) |
| Phase 2a | Multiple ascending dose | AD/MCI patients | CSF biomarkers, safety, cognitive endpoints |
| Phase 2b | Biomarker-guided enrichment | Early AD/PD | Progression markers, efficacy signals |

Competitive Landscape

Several HDAC6 inhibitors are in development:

| Compound | Company | Stage | Notes |
|---------|---------|-------|-------|
| Tubastatin A | Academic | Preclinical | First-generation, limited CNS penetration |
| Tubathianin A | --- | Preclinical | Natural product, improved potency |
| ACY-1215 (Ricolinostat) | Acetylon/celgene | Phase 1/2 (oncology) | Good safety profile, some CNS exposure |
| CKD-506 | CKD Pharma | Phase 1 | Designed for CNS indications |
| HDAC6i | Various | Preclinical | Next-generation with BBB penetration |

Biomarkers for Development

• Target engagement: Platelet HDAC6 activity, α-tubulin acetylation in PBMCs
• Pharmacodynamic: CSF tau acetylation, autophagy markers (LC3, p62)
• Efficacy signals: CSF neurofilament light chain (NfL), amyloid/tau PET

Dosing Protocol

Recommended Approach

Phase 1 (Weeks 1-4)

• Dose-finding in healthy volunteers
• Establish MTD and RP2D
• PK/PD modeling

Phase 2 (Weeks 5-16)

• AD: 50-200mg daily
• PD: 50-200mg daily
• Monitor: cognitive batteries, CSF biomarkers, safety

Phase 3 (ongoing)

• Long-term extension studies
• Disease modification endpoints

Combination Potential

HDAC6 inhibition synergizes with:

Autophagy inducers (TFEB activators, rapamycin) — enhanced clearance

Hsp90 inhibitors — dual proteostasis restoration

Microtubule stabilizers — complementary axonal transport

NAD+ precursors — energy metabolism support

Anti-aggregation compounds — reduced protein burden

Risk Assessment

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Off-target HDAC inhibition | Low | Highly selective compounds exist |
| Immunosuppression | Low | Peripheral vs CNS activity separable |
| Hematologic toxicity | Medium | Monitor CBC, dose adjustment |
| CNS side effects | Low-Medium | Start low, titrate gradually |

Competitive Advantages

Well-validated mechanism — strong preclinical data across disease models

CNS-penetrant compounds emerging — next-gen inhibitors designed for brain

Biomarker-ready — acetylation status measurable in accessible tissues

Combination potential — synergies with multiple pipeline assets

Broad indication potential — applicable to AD, PD, ALS, HD

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10 | HDAC6 inhibitors in development; CNS application remains novel |
| Mechanistic Rationale | 9/10 | HDAC6 uniquely positioned to regulate autophagy, tubulin, and Hsp90 - key neuronal pathways |
| Addresses Root Cause | 7/10 | Targets proteostasis and microtubule dysfunction, important disease mechanisms |
| Delivery Feasibility | 6/10 | BBB penetration challenging; several brain-penetrant HDAC6 inhibitors in pipeline |
| Safety Plausibility | 7/10 | Selective HDAC6 inhibition has better safety profile than pan-HDAC inhibitors |
| Combinability | 8/10 | Compatible with amyloid, tau, alpha-synuclein targeted therapies |
| Biomarker Availability | 7/10 | Acetyl-tubulin, Hsp90 acetylation can serve as pharmacodynamic markers |
| De-risking Path | 7/10 | Clear regulatory pathway; several candidates in clinical trials |
| Multi-disease Potential | 8/10 | High potential: AD, PD, ALS, Huntington's disease, aging |
| Patient Impact | 7/10 | Could improve protein clearance and neuronal resilience |

Total: 73/100

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](diseases/huntingtons)

Mechanisms

• [Autophagy](/entities/autophagy)
• [Proteostasis](/mechanisms/proteostasis-network)
• HDAC6 Signaling
• Microtubule Dynamics
• [Protein Aggregation](/mechanisms/protein-aggregation)

Proteins

• [HDAC6](/entities/hdac6)
• [Alpha-Tubulin](/entities/alpha-tubulin)
• [HSP90](entities/hsp90-protein)
• [Tau (MAPT)](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• p62/SQSTM1

Cell Types

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• Tubastatin A
• ACY-1215 (Ricolinostat
• HDAC6 Inhibitors

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Proteostasis Network](/mechanisms/proteostasis-network)
• Autophagy-Lysosome Pathway
• [Tau Pathology](/mechanisms/tau-pathology)

External Links

• [PubMed: HDAC6 Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=HDAC6+neurodegeneration)
• [ClinicalTrials.gov: HDAC6](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=HDAC6)

Actionable Next Steps

Short-term (1-3 months)

Literature scan: Conduct systematic review of HDAC6 inhibitor preclinical studies in AD/PD models (PubMed search, capture key efficacy metrics)

Competitive analysis: Map HDAC6 inhibitor pipeline - companies, compounds, development stage, CNS penetration data

Biomarker validation: Identify biomarker readouts (platelet HDAC6 activity, tubulin acetylation in PBMCs) for target engagement

Medium-term (3-6 months)

Scientific advisory: Consult with HDAC6 biology experts (academic labs: d'Ydewalle, Muchowski) on optimal compound selection

Regulatory strategy: Pre-IND meeting with FDA to discuss design for AD/PD indication

Partnership outreach: Initiate discussions with Acetylon/Celgene, CKD Pharma on compound licensing or collaboration

Long-term (6-12 months)

IND-enabling studies: Contract GLP toxicology, GMP manufacturing for lead compound

Clinical trial design: Finalize Phase 1/2a protocol with biomarker enrichment strategy

Patient stratification: Develop biomarker panel for patient selection (baseline acetylation status, disease stage)

Key Milestones

| Milestone | Target | Dependencies |
|-----------|--------|--------------|
| Literature scan complete | Month 1 | None |
| Partnership term sheet | Month 4 | Competitive analysis, regulatory feedback |
| IND submission | Month 12 | GLP toxicology complete |
| First patient dosed | Month 14 | IND clearance |

Implementation Roadmap

Phase 1: Preclinical Development (Months 1-12)

Objective: Complete IND-enabling studies and select lead compound

| Activity | Timeline | Cost | Go/No-Go Criteria |
|----------|----------|------|------------------|
| Lead compound selection | Months 1-2 | $150K | CNS penetration >30%, brain/plasma ratio acceptable |
| GLP toxicology (rodent) | Months 3-7 | $800K | MTD >10x human dose, no off-target HDAC |
| GLP toxicology (non-rodent) | Months 5-9 | $600K | No significant organ toxicity at 28 days |
| GMP manufacturing | Months 6-10 | $400K | >99% purity, stable 24 months |
| IND package compilation | Months 9-11 | $200K | All GLP studies complete |
| IND submission | Month 12 | $100K | FDA acceptance |

Total Phase 1 Cost: $2.25-2.75M

Phase 2: Early Clinical Development (Months 12-30)

Objective: Establish safety and preliminary efficacy in AD/PD patients

| Activity | Timeline | Cost | Key Endpoints |
|----------|----------|------|---------------|
| Phase 1 (first-in-human) | Months 12-16 | $2.5M | Safety, PK/PD, MTD |
| Phase 2a (AD cohort) | Months 16-26 | $4.5M | Biomarker (CSF tau, p-tau217), cognition |
| Phase 2a (PD cohort) | Months 18-28 | $4.0M | Motor scores, biomarker (α-syn) |
| Biomarker development | Months 12-24 | $500K | Validated acetylation assay |

Total Phase 2 Cost: $10.5-12.5M

Phase 3: Pivotal Development (Months 28-48)

Objective: Demonstrate disease modification in registrational trials

| Activity | Timeline | Cost | Design |
|----------|----------|------|--------|
| Phase 2b/3 AD | Months 28-42 | $18-25M | Randomized, placebo-controlled, biomarker enrichment |
| Phase 2b/3 PD | Months 32-46 | $15-22M | Similar design, motor endpoints |
| Regulatory submissions | Months 44-48 | $3M | NDA/MAA filings |

Total Phase 3 Cost: $36-50M

Total Program Cost: $49-65M over 48 months

Risk-Adjusted Scenarios

| Scenario | Probability | Adjusted Cost |
|----------|-------------|---------------|
| Base case | 50% | $57M |
| Accelerate (fast track) | 25% | $49M (savings from overlapping phases) |
| Delay (toxicity) | 25% | $72M (+25% for extended development) |

Academic Center Recommendations

AD: UC San Diego (Paul Aisen), Washington University in St. Louis (John Morris)

PD: University of Pennsylvania (Weintraub), Columbia (Ray Dorsey)

Biomarker labs: Banner Sun Health Research Institute, University of Kentucky

Industry Partnership Strategy

Tier 1 Targets (existing HDAC6 programs):

• Acetylon/Celgene: Has ACY-121 (ricolinostat), consider in-licensing
• CKD Pharma: Korean company with CNS-penetrant HDAC6i

Tier 2 Targets (broad neurodegeneration):

• Biogen: Interest in AD combination therapies
• AbbVie: Neuro immunology pipeline

Tier 3 Targets (repositioning):

• Generic companies: Tubastatin A analogs, repositioning opportunity

Decision Gates

| Gate | Criteria | Consequence |
|------|----------|-------------|
| Lead selection | Brain exposure >30% of plasma | Proceed to tox |
| IND acceptance | No clinical hold | Start Phase 1 |
| Phase 1 complete | Safety profile acceptable | Phase 2a |
| Phase 2a | biomarker + signal >20% | Phase 2b/3 |
| Phase 2b | Confirmed disease modification | File NDA | Page created: 2026-03-14 Last updated: 2026-03-14 22:30 PT

References

[Simões-Pires C, Zwick V, Nurisso A, et al, HDAC6 as a target for neurodegenerative diseases: what makes it different from other HDACs? (2013)](https://pubmed.ncbi.nlm.nih.gov/24367916/)

[d'Ydewalle C, Bhardwaj R, Kumar M, et al, HDAC6 inhibitors reverse axonal transport defects in disease models (2012)](https://pubmed.ncbi.nlm.nih.gov/21820195/)

[Govindarajan N, Rao P, Bhardwaj R, et al, Hypermethylation and hypoacetylation: tipping the balance in Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23142221/)

[Zhang L, Liu C, Wu J, et al, Tubastatin A/ACY-1215 improves cognition and reduces pathology in Alzheimer's disease models (2017)](https://pubmed.ncbi.nlm.nih.gov/28651956/)

[Chen L, Chen M, Luo G, et al, HDAC6 inhibitor protects against 6-OHDA-induced damage in Parkinson's disease models through autophagy enhancement (2020)](https://pubmed.ncbi.nlm.nih.gov/32654267/)

[Du Y, Wang J, Li H, et al, HDAC6 inhibition reduces α-synuclein accumulation in models of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32060184/)

[Taes I, Timmers M, Hersmus N, et al, HDAC6 inhibition in ALS: preclinical evidence and clinical development (2013)](https://pubmed.ncbi.nlm.nih.gov/24067536/)

[Dompierre JP, Godin JD, Charrin BC, et al, Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation (2007)](https://pubmed.ncbi.nlm.nih.gov/17428498/)

Pathway Diagram

The following diagram shows the key molecular relationships involving HDAC6 Modulation Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis: